Early Outcomes of Repetitive Transcranial Magnetic Stimulation in Complex Clinical Population

Introduction Repetitive Transcranial Magnetic Stimulation (rTMS) is a new emerging neuromodulation treatment that has been tried for multiple psychiatric conditions [1, 2]. Its major approved application treatment-resistant depression (TRD) [1]. At the same time there perceived potential its use other clinical conditions, primarily mood and anxiety disorders [2]. Homewood Health Centre we have using rTMS as an adjunct patients with TRD comorbidities. Objectives To evaluate effectiveness feasibility of in complex populations. Methods Observational study. Quick Inventory Depressive Symptomatology (QIDS). Generalized Anxiety Disorder Questionnaire (GAD-7). Descriptive statistics. Results We treated 30 patients, 12 women (40%) 18 men (60%), average age 42.0±15.6 years. All had primary diagnosis depressive disorder. The standard questionnaires were used to quantify severity symptoms (QIDS) baseline scores 16.1±4.9 15.0±4.4, respectively. received 28.1±5.1 treatments. but one full course planned. end-of-treatment (EoT) 9.6±6.5 7.3±5.3, rates improvement remission 66.7% 36.7%, 76.9% 30.8%, Image: Conclusions Our data indicate provides significant recovery populations well-tolerated. While further research required, recommend wider implementation disorders. References 1. Brunoni AR, Chaimani A, Moffa AH, Razza LB, Gattaz WF, Daskalakis ZJ, Carvalho AF: Acute Treatment Major Episodes. JAMA Psychiatry 2017, 74(2):143. 2. Somani Kar SK: Efficacy repetitive transcranial magnetic stimulation depression: evidence thus far. Gen Psychiatr 2019, 32(4):e100074. Disclosure Interest None Declared